Ceribell Inc Revenue Growth Rates (CBLL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ceribell Inc   (NASDAQ: CBLL)
 

CBLL's Revenue Growth by Quarter and Year

Ceribell Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CBLL/growth
https://api.csimarket.com/api/v1/companies/CBLL/fundamentals
https://api.csimarket.com/api/v1/companies/CBLL/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
CBLL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 29.34
2nd Quarter June 28.10
1st Quarter March 26.12
FY 83.56





CBLL Revenue third quarter 2026 Y/Y Growth Comment
Ceribell Inc achieved in the third quarter 2026, above Company average Revenue growth of 33.73% year on year, to $ 29.34 millions.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 37 other companies have achieved higher Revenue growth. While Ceribell Inc ' s Revenue rise of 33.73% ranks overall at the positon no. 633 in the third quarter 2026.


CBLL Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 33.73 %
2nd Quarter June 35.88 %
1st Quarter March 30.53 %
FY   -

Financial Statements
Ceribell Inc 's third quarter 2026 Revenue $ 29.34 millions CBLL's Income Statement
Ceribell Inc 's third quarter 2025 Revenue $ 21.94 millions Quarterly CBLL's Income Statement


CBLL Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 4.42 %
2nd Quarter June 7.58 %
1st Quarter March 1.87 %
FY (Year on Year)   -


Back to CBLL Growth rate Comparisons >> Back to CBLL Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #38
Healthcare Sector #150
Overall #633

Revenue Y/Y Growth Statistics
High Average Low
46.51 % 26.17 % -44.86 %
(Jun 30 2025)   (Dec 31 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #38
Healthcare Sector #150
Overall #633
Revenue Y/Y Growth Statistics
High Average Low
46.51 % 26.17 % -44.86 %
(Jun 30 2025)   (Dec 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ceribell Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
189.5 % 18.4 % -57.16 %
(Dec 31 2023)  


CBLL's III. Quarter Q/Q Revenue Comment
Ceribell Inc achieved in the III. Quarter 2026 below company average Revenue growth of 4.42% quarter on quarter, to $ 29.34 millions.

Within Medical Equipment & Supplies industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Ceribell Inc 's Revenue growth quarter on quarter, overall rank is 970.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #41
Healthcare Sector #146
Overall #970
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #41
Healthcare Sector #146
Overall #970
Revenue Q/Q Growth Statistics
High Average Low
189.5 % 18.4 % -57.16 %
(Dec 31 2023)  


CBLL's III. Quarter Q/Q Revenue Comment
Ceribell Inc achieved in the III. Quarter 2026 below company average Revenue growth of 4.42% quarter on quarter, to $ 29.34 millions.

Within Medical Equipment & Supplies industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Ceribell Inc 's Revenue growth quarter on quarter, overall rank is 970.


Ceribell Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 109.20
Y / Y Revenue Growth (TTM) 34.54 %
Year on Year Revenue Growth Overall Ranking # 367
Seqeuential Revenue Change (TTM) 7.27 %
Seq. Revenue Growth (TTM) Overall Ranking # 1908


Cumulative Revenue growth Comment
Ceribell Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 34.54% year on year, to $ 109 millions if the fiscal year would have ended in Sep 30 2026.
Ceribell Inc 's trailing twelve months Revenue growth was higher than company's average 12.45% and higher than 33.54% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 7.27 % from $101.8 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at12.45%.

In the Healthcare sector 99 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 367.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 107
Healthcare Sector # 100
Overall # 367

Revenue TTM Y/Y Growth Statistics
High Average Low
41.38 %
 12.45 %
-7.06 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 107
Sector # 295
S&P 500 # 1908
Cumulative Revenue growth Comment
Ceribell Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 34.54% year on year, to $ 109 millions if the fiscal year would have ended in Sep 30 2026.
Ceribell Inc 's trailing twelve months Revenue growth was higher than company's average 12.45% and higher than 33.54% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 7.27 % from $101.8 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at12.45%.
The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 7.27 % increase from $101.8 millions in the period from Jun 30 2026 to Sep 30 2025.

In the Healthcare sector 99 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 367.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 107
Healthcare Sector # 100
Overall # 367

Revenue TTM Y/Y Growth Statistics
High Average Low
41.38 %
12.45 %
-7.06 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 107
Sector # 295
S&P 500 # 1908




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CBLL's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Yunhong Green Cti Ltd 51.28%$ 51.282 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions


About Ceribell Inc Revenue Growth Rates (CBLL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ceribell Inc (CIK 1861107).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-445555
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ceribell Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.